Ken Griffin Amarin Corp Plcuk Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.57 - $0.8 $15,275 - $21,440	26,800 Added 57.14%	73,700 $46,000
Q2 2024 Aug 14, 2024	SELL	$0.63 - $1.07 $21,609 - $36,701	-34,300 Reduced 42.24%	46,900 $32,000
Q1 2024 May 15, 2024	SELL	$0.82 - $1.35 $1,886 - $3,105	-2,300 Reduced 2.75%	81,200 $72,000
Q4 2023 Feb 14, 2024	BUY	$0.66 - $0.91 $8,184 - $11,284	12,400 Added 17.44%	83,500 $72,000
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.43 $52,020 - $87,516	-61,200 Reduced 46.26%	71,100 $65,000
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.49 $2,016 - $2,682	1,800 Added 1.38%	132,300 $157,000
Q1 2023 May 15, 2023	SELL	$1.19 - $2.19 $30,107 - $55,407	-25,300 Reduced 16.24%	130,500 $195,000
Q4 2022 Feb 14, 2023	SELL	$1.07 - $1.34 $92,662 - $116,044	-86,600 Reduced 35.73%	155,800 $188,000
Q3 2022 Nov 14, 2022	SELL	$1.09 - $1.67 $110,962 - $170,006	-101,800 Reduced 29.58%	242,400 $264,000

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $185M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.